Amgen Inc. Agrees to Purchase Dublin-based Horizon Therapeutics Plc. for €24.7 Billion Amgen Inc. has agreed to buy Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26 billion), in a deal that could face further delays or a breakdown in negotiations. Following Sanofi's withdrawal from the race, c...Find More
Today, the increasing prevalence of Chronic Respiratory Diseases (CRDs) is one of the leading health challenges worldwide. CRDs affect hundreds of millions of people and cause huge mortality, morbidity, immense socio-economic burden, and disability-adjusted life years (DALYs). Over the past few decades, si...Find More
Cancer-killing virus flees immune destruction and attacks metastatic lung tumors in mice Several viruses have a natural ability to eliminate cancer; however translating them into treatments has proven difficult, partly due to the immune system tends to kill them before they can reach cancer cells. Researchers fr...Find More
FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...Find More
Slowly or rapidly growing bacteria- Nontuberculous mycobacteria (NTM), might appear innocuous, however, NTM infections have a notably higher total prevalence of 3,65,273 in the 7MM, estimates DelveInsight. Despite the global prevalence, clear from the facts and figures, the available therapies are entirely on an in...Find More
Nontuberculous Mycobacteria (NTM) is a ubiquitous, aerobic, non-motile, acid-fast bacteria, which, when inhaled, may cause severe lung disorders. Especially common in the elderly, individuals with lung diseases, slender caucasian women, and people with esophageal disorders, NTM affects both healthy persons and thos...Find More
The US FDA today has given its nod to Trikafta (elexacaftor/ivacaftor/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patients with cystic fibrosis. The drug, Trikafta, has been approved for patients of age 12 years and older who have at least one F508del mutation...Find More
Cystic fibrosis (CF) manifests as a clinical syndrome characterized by chronic sinopulmonary infection as well as by gastrointestinal, nutritional, and other abnormalities. Lung damage secondary to chronic infection is the main determinant of morbidity and mortality in individuals with cystic fibrosis. CF indivi...Find More
A New Approach to treat Cystic Fibrosis Researchers at the University of Illinois in Champaign have found that anti-fungal drug amphotericin that helps lung cells to fight chronic bacterial lung infection can help in treating Cystic Fibrosis- a genetic disorder that causes serious damages to lungs. The finding ...Find More
Kalydeco, the first Cystic Fibrosis drug of Vertex, got approved for infants The Food and Drug Administration has cleared Kalydeco drug of Vertex Pharmaceuticals for infants aged 12 to under 24 months. The approved drug treats the underlying cause of cystic fibrosis in children of this age with at least one mutatio...Find More
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.